Publications by authors named "Frank Boess"

Claim this Profile
D
Development of a quantitative semi-mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q-ATN model).
Norman A Mazer, Carsten Hofmann, Dominik Lott, Ronald Gieschke, Gregory Klein, Frank Boess

Alzheimers Dement· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Gennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, Maddalena Marchesi, Tanya Simuni, Frank G Boess

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Gennaro Pagano, Frank G Boess, Kirsten I Taylor, Benedicte Ricci, Brit Mollenhauer

Front Neurol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns in Patients with Incident Parkinson's Disease in the United States.
Richard Houghton, Frank Boess, Lynne Verselis, Yingjie Ding, Rita Freitas

J Parkinsons Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of 3 Novel Tau Radiopharmaceuticals, C-RO-963, C-RO-643, and F-RO-948, in Healthy Controls and in Alzheimer Subjects.
Dean F Wong, Robert A Comley, Hiroto Kuwabara, Paul B Rosenberg, Susan M Resnick, Frank Boess

J Nucl Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
Joseph Jankovic, Ira Goodman, Beth Safirstein, Tonya K Marmon, Dale B Schenk, Frank G Boess

JAMA Neurol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive Decline in Gray and White Matter Integrity in Parkinson's Disease: An Analysis of Longitudinal Parkinson Progression Markers Initiative Diffusion Tensor Imaging Data.
Kirsten I Taylor, Fabio Sambataro, Frank Boess, Alessandro Bertolino, Juergen Dukart

Front Aging Neurosci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
Florian Lipsmeier, Kirsten I Taylor, Timothy Kilchenmann, Detlef Wolf, Alf Scotland, Frank Boess

Mov Disord· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.
Dan Ziegler, Edith Schneider, Frank G Boess, Lovisa Berggren, Frank Birklein

J Diabetes Complications· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: results from a German observational study.
Michael Happich, Edith Schneider, Frank G Boess, Stefan Wilhelm, Alexander Schacht

Clin J Pain· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
Hartmut Porst, Mauro Gacci, Hartwig Büttner, Carsten Henneges, Frank Boess

Eur Urol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Jacques Buvat, Hartwig Büttner, Konstantinos Hatzimouratidis, Pedro A S Vendeira, Ignacio Moncada, Frank G Boess

J Sex Med· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
Frank G Boess, Jean de Vry, Christina Erb, Timo Flessner, Martin Hendrix

Psychopharmacology (Berl)· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability aspects in duloxetine-treated patients with depression: Should one use a lower starting dose in clinical practice?
Stefan Wilhelm, Frank G Boess, Ulrich Hegerl, Roland Mergl, Michael Linden

Expert Opin Drug Saf· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
Jos Prickaerts, Nick P van Goethem, Richard Chesworth, Gideon Shapiro, Frank G Boess

Neuropharmacology· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.
Viktor Lakics, Eric H Karran, Frank G Boess

Neuropharmacology· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of behavioural and long-term potentiation models in the development of memory-improving drugs.
Arjan Blokland, Frank Boess

Expert Opin Drug Discov· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Frank G Boess, Jean De Vry, Christina Erb, Timo Flessner, Martin Hendrix

J Pharmacol Exp Ther· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.
Frank G Boess, Martin Hendrix, Franz-Josef van der Staay, Christina Erb, Rudy Schreiber

Neuropharmacology· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.
Marja Van Kampen, Karin Selbach, Renate Schneider, Elleonore Schiegel, Frank Boess

Psychopharmacology (Berl)· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis